Syros Pharmaceuticals
Présence
Syros Pharmaceuticals est une société cotée sous le symbole boursier SYRS (US).
Acquisition, funding and merger involving Syros Pharmaceuticals.
- Syros Pharmaceuticals has announced the acquisition of Tyme Technologies (publié le 29 novembre 2022).
- Syros Pharmaceuticals vient d'annoncer une levée de fonds de 190 millions de dollars. (publié le 5 juillet 2022).
- Syros Pharmaceuticals has announced the acquisition of Tyme Technologies (publié le 5 juillet 2022).
Dirigeants
Voir l'organigramme avec ses 17 principaux dirigeants
Biographies les plus recherchées chez Syros Pharmaceuticals
Changements de dirigeants chez Syros Pharmaceuticals
- Nancy Simonian qui est Director, President, Chief Executive Officer and Principal Financial Officer, deviendra Director le 2 déc. 2023 (publié le 3 octobre 2023).
- Conley Chee qui est Chief Commercial Officer, sera promu Chief Executive Officer le 2 déc. 2023 (publié le 3 octobre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Syros Pharmaceuticals.
Pharmacie
Syros Pharmaceuticals a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Syros Pharmaceuticals
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update :: Syros Pharmaceuticals, Inc. (SYRS)
- Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros to Participate in TD Cowen 44th Annual Health Care Conference :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine :: Syros Pharmaceuticals, Inc. (SYRS)
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Syros Pharmaceuticals
- Syros Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Syros Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Conley Chee 
Appelez Syros Pharmaceuticals au +1 617...
